CELANESE CORPORATION (CE): what the price requires

At today's price, CELANESE CORPORATION (CE) is priced for +7.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/CE

Headline

FieldValue
TickerCE
CompanyCELANESE CORPORATION
Current price$47.32/sh
CompositionEngineered Materials 56% / Acetyl Chain 44%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed4.8%
Operating margin (mid-cycle)6.7%
Margin compression implied-1.9pp
Trailing margin (depressed year)-6.9%
Implied growth7.4%
Multiple paid27x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~9pp (computed at the 7% minimum rate; the CAPM rate 6.2% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~5.2 years; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.11σ
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.42x3expensive
Earnings0.94x1justifies
Relative0.37x2justifies
Growth1.27x2expensive

Families that justify the price: Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 3.0%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
DCF Exit MultipleGrowth$72.840.65xyesExit EV/EBITDA: 483.2x / 485.2x / 487.2x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$129.460.37xyesP/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$36.941.28xyesReference only (book value floor): BV/sh $36.94, ROE negative
Two-Stage Excess ReturnAsset$33.251.42xyesReference only (book value with convergence): BV/sh $36.94, ROE converges to ke
Discounted Future Market CapGrowth$24.941.90xyesRev $9.5B, growth -6% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.5x / 0.6x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$50.500.94xyesNormalized EBIT (5y avg op income, one-time charges added back) $1.00B × (1−40%) / WACC 3.0% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$0.014731.50xyesEBITDA $0.04B × sector EV/EBITDA 8.0x (excluded from median)
FCF YieldEarnings$0.014731.50xyesFCF $878.0M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.014731.50xyesSBC-adj FCF $0.85B (FCF $0.88B − SBC $0.03B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$8.525.55xyesBV $36.94 × (ROIC 0.7% / WACC 3.0%)
P/Sales SectorRelative$129.460.37xyesRevenue $9.49B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$14.5b
Net debt / NOPAT (after-tax)37.20x
Net debt / operating income (pre-tax)22.23x
Interest coverage0.9x
Share count CAGR (dilution)0.2%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 6.7%); the trailing year was depressed.

Bullet Takeaways

Celanese is a cyclical chemicals business at a trough, so the numbers have to be read through the cycle, not at the bottom. Trailing operating income is negative, so the inversion normalizes to through-cycle margins: at $51.18 the price pays about 27x mid-cycle operating income, implying roughly 8.1% operating-profit growth for five years.

The price is supported by the earnings-power, relative-multiple, and growth-DCF families (relative valuation near $129, perpetual-growth DCF near $117, Earnings Power Value near $41), while the asset and cash-flow methods read it as expensive or are pinned near zero by the depressed trailing cash flow.

The whole thesis is the balance sheet. Net debt is about $14.5 billion against negative trailing operating income, interest coverage is roughly 0.9x on a trailing basis, and management is running a multi-year deleveraging plan targeting net debt below $9 billion. The dividend was cut to $0.03 a quarter to redirect cash to debt. This is a recovery-and-deleverage bet, not a steady compounder.

Bull Case

Read Celanese as what it is: a mature, asset-heavy chemicals producer at the bottom of its cycle, which means the trailing numbers understate the business and the question is what normalized earnings look like on the other side. The company runs two segments, Engineered Materials at roughly 56% and the Acetyl Chain at roughly 44%, across what the 10-K describes as '51 global production facilities and an additional 20 strategic affiliate production facilities' employing more than 11,000 people (FY2025 10-K, accession 0001306830-26-000031). This is a real industrial franchise with scale in acetyls and engineered polymers, not a speculative story. Because trailing operating income is negative, the inversion does the sensible thing and applies the company's own through-cycle margins to current revenue, which puts the priced-in bar at about 8.1% operating-profit growth, within what Celanese has historically delivered when the cycle turns.

The recovery is already showing in the prints. Q1 2026 EPS came in at $0.41, a swing from a $0.15 loss a year earlier, and management guided full-year 2026 adjusted EPS to $2.00 to $2.40 with Q2 expected to be the strongest quarter of the year. The turnaround levers are concrete: strategic asset closures, a product-mix shift toward higher-margin specialty markets, a nylon restructuring, and over $100 million of inventory reduction in engineered materials. The earnings-power valuation method already lands near $41 on trough-influenced numbers; if mid-cycle margins return, the operating leverage in a high-fixed-cost chemicals business is substantial.

The deleveraging plan is the value-creation engine, and it is running. Celanese generated $773 million of free cash flow in 2025, fully repaid its term-loan balance, divested Micromax for $500 million, refinanced near-term maturities, and is targeting roughly $2.5 billion of net debt reduction through 2027 toward a goal of under $9 billion. The dividend was cut to a token $0.03 per quarter precisely to redirect cash to the balance sheet, which is the right priority for an over-levered equity. In a deleveraging story the equity is a call option on the enterprise: as debt falls and mid-cycle earnings recover, value transfers from creditors to shareholders.

Bear Case

The variable with the most leverage on this thesis is not demand growth; it is the spread between product prices and raw-material costs, and that spread is outside management's control. Celanese itself lists among its core risks 'volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp' and the inputs to its nylon chain (FY2025 10-K, accession 0001306830-26-000031). The filing also notes that for parts of the portfolio, margins are tied to value-in-use and are 'generally independent of changes in the cost of raw materials,' so margins 'may expand or contract in response to changes in raw material costs.' In plain terms, an over-levered company is running a business whose profitability swings with commodity and energy markets, and the recovery the price assumes requires those markets to cooperate for years.

The balance sheet is where commodity volatility becomes existential rather than merely cyclical. Net debt of about $14.5 billion against negative trailing operating income leaves trailing interest coverage near 0.9x, meaning the business did not cover its interest at the trough. The deleveraging plan depends on free cash flow that itself depends on the cyclical recovery actually arriving; the company guides to $650 million to $750 million of free cash flow in 2026, but a chemicals downturn that lingers, a refinancing window that closes, or another ratings downgrade would all pressure a plan with little margin for error. The dividend cut to $0.03 is honest, but it is also a signal: this equity has been subordinated to its creditors until the leverage comes down.

The third risk is that the trough is structural in places, not just cyclical. The nylon restructuring and asset closures are management's admission that some assets cannot earn their cost of capital in the current environment, much of it driven by Chinese capacity additions in commodity chemicals and persistent European energy costs. If demand in autos and industrials stays soft and Chinese supply keeps pressuring the Acetyl Chain, mid-cycle margins may reset lower than history suggests, which would invalidate the normalized-earnings assumption the entire inversion rests on. At 27x mid-cycle operating income with each point of cost of capital moving the implied growth bar by about 9 points, the price has limited tolerance for a recovery that is slower, shallower, or later than planned, on top of a debt load that does not wait.

Valuation

Celanese is the case where the headline multiple is meaningless because trailing earnings are negative. The valuation has to normalize, and the inversion does: it applies the company's own through-cycle margins to current revenue rather than the trough quarter, producing a price that pays about 27x mid-cycle operating income and implies roughly 8.1% operating-profit growth held for five years, computed at a 7% cost of capital with 4% terminal growth. That growth rate is within what the business has delivered coming out of past cycles, so the stretch is in durability and in whether mid-cycle margins are still what history says.

The method families split along the cyclical fault line. The forward-growth and relative-multiple frames, which look through the trough, land high: perpetual-growth DCF near $117, relative valuation and P/Sales near $129, exit-multiple DCF near $75. The asset and excess-return methods land near $33 to $37, and the cash-flow-yield and EV/EBITDA methods are effectively pinned at zero because trailing EBITDA and free cash flow are depressed, which is a mechanical artifact of the trough rather than a real read on value. So on normalized assumptions the equity looks cheap. The honest caveat is that every one of those above-price figures depends on the cycle recovering and the balance sheet surviving the wait. This is a valuation that is genuinely attractive if mid-cycle earnings return and genuinely dangerous if the leverage forces the issue first. The investment question is not whether Celanese is cheap on normalized numbers (it is); it is whether the company has enough liquidity and time to let the normalization happen.

Catalysts

The earnings cadence is the near-term catalyst. Q1 2026 delivered EPS of $0.41 against a year-ago loss, and management guided full-year 2026 adjusted EPS to $2.00 to $2.40 with Q2 framed as the highest-earnings quarter of the year followed by gradual second-half moderation. That makes the Q2 print the key confirmation of whether the recovery is tracking, and the second-half trajectory the test of whether the moderation is orderly. Free cash flow guidance of $650 million to $750 million for 2026 is the number that funds the deleveraging, so cash conversion matters as much as the EPS line.

The deleveraging milestones are the structural catalysts. Celanese is targeting roughly $2.5 billion of net debt reduction through 2027 toward under $9 billion, having already repaid its term loans, divested Micromax for $500 million, and refinanced near-term maturities. Further asset sales, any change in credit rating, and progress on the nylon restructuring would each move the equity, because in a levered turnaround the debt path is the value path. The macro watch items are the ones the filing names: ethylene, methanol, and natural-gas prices, Chinese acetyls capacity, and end-demand in autos and industrials. A firming chemicals cycle accelerates everything; a prolonged trough threatens the plan. Note the dividend is now a token $0.03 per quarter, redirected to debt, so this is not an income name during the repositioning.

Sources: Celanese cuts dividend for debt reduction (Finimize), Celanese Q1 2026 8-K (SEC), Celanese deleveraging and free cash flow outlook (Simply Wall St), Celanese FY2025 10-K.

Peer Cohorts (Per Segment, With Filing Citations)

Engineered Materials (reported)

Acetyl Chain (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive CE report on boothcheck